Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
An open source extrusion bioprinter based on the E3D motion system and tool changer to enable FRESH and multimaterial bioprinting
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.ORCID iD: 0000-0003-3117-5367
Show others and affiliations
2021 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 11, no 1, article id 21547Article in journal (Refereed) Published
Abstract [en]

Bioprinting is increasingly used to create complex tissue constructs for an array of research applications, and there are also increasing efforts to print tissues for transplantation. Bioprinting may also prove valuable in the context of drug screening for personalized medicine for treatment of diseases such as cancer. However, the rapidly expanding bioprinting research field is currently limited by access to bioprinters. To increase the availability of bioprinting technologies we present here an open source extrusion bioprinter based on the E3D motion system and tool changer to enable high-resolution multimaterial bioprinting. As proof of concept, the bioprinter is used to create collagen constructs using freeform reversible embedding of suspended hydrogels (FRESH) methodology, as well as multimaterial constructs composed of distinct sections of laminin and collagen. Data is presented demonstrating that the bioprinted constructs support growth of cells either seeded onto printed constructs or included in the bioink prior to bioprinting. This open source bioprinter is easily adapted for different bioprinting applications, and additional tools can be incorporated to increase the capabilities of the system.

Place, publisher, year, edition, pages
Springer Nature Springer Nature, 2021. Vol. 11, no 1, article id 21547
National Category
Biomaterials Science
Identifiers
URN: urn:nbn:se:uu:diva-459007DOI: 10.1038/s41598-021-00931-1ISI: 000714415600079PubMedID: 34732783OAI: oai:DiVA.org:uu-459007DiVA, id: diva2:1614627
Funder
Swedish Cancer Society, 20 1285 PjFAvailable from: 2021-11-26 Created: 2021-11-26 Last updated: 2026-03-18Bibliographically approved
In thesis
1. Applications of Additive Manufacturing for Advancing Cell Models from 2D to 3D
Open this publication in new window or tab >>Applications of Additive Manufacturing for Advancing Cell Models from 2D to 3D
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Two-dimensional (2D) cell culture systems are widely used in preclinical research due to their ease of handling and standardisation, but do not adequately reflect key aspects of the complex three-dimensional (3D) physiological microenvironment. This limits the predictive value of in vitro studies for both drug development and biomaterials research. The overall aim of this thesis was to explore how additive manufacturing supports the transition from 2D to more advanced 3D cell culture models.

In Study I, CombiCTx, a cell culture device for combinatorial anti-cancer drug testing, was developed. The system enables the formation of overlapping drug gradients through diffusion in a hydrogel matrix, and an assay and imaging analysis protocol was established. Using breast cancer cells, it was demonstrated that the assay can identify synergistic drug effects and that, for the drugs tested, these effects were spatially confined to specific regions of the assay space, highlighting the importance of diffusion processes not captured in standard 2D assays.

In Study II, an open source extrusion-based bioprinter based on the E3D motion system was established to increase accessibility to bioprinting technologies. The system supports multimaterial printing and FRESH bioprinting. Collagen scaffolds and cell-laden laminin-containing constructs were printed, and high cell viability was maintained, demonstrating the suitability of the platform for generating 3D cell culture environments.

Studies III and IV focused on biomaterials for bone regeneration. In Study III, the biosafety of a phosphoserine (pSER)-modified calcium phosphate bone adhesive was evaluated. Both in vitro and in vivo results indicated good biocompatibility, with no evidence of adverse immune reactions or ectopic bone formation.

In Study IV, 3D bioprinted collagen-silica hybrid scaffolds modified with pSER were investigated. In vitro experiments showed a dose-dependent effect of pSER in combination with calcium phosphate on cell viability. In vivo, mineralised scaffolds promoted bone formation, suggesting an osteogenic potential of these materials.

In conclusion, the studies presented in this thesis demonstrate that additive manufacturing can be used to develop more advanced in vitro models and to investigate biomaterials in controlled 3D environments. These approaches will contribute to improving the translation of preclinical findings into clinical applications.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2026. p. 73
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2248
Keywords
3D printing, additive manufacturing, 3D bioprinting, in vitro, biomaterials, combinatorial drug screening, bioink
National Category
Medical Biotechnology
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-582589 (URN)978-91-513-2779-2 (ISBN)
Public defence
2026-05-08, A1:107a, Biomedical Center (BMC), Husargatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2026-04-16 Created: 2026-03-18 Last updated: 2026-04-16

Open Access in DiVA

fulltext(2152 kB)440 downloads
File information
File name FULLTEXT01.pdfFile size 2152 kBChecksum SHA-512
8041613de180b7cee8f0603d8fe8d8c5768fca697e7226f246c63a60d0fda5bc9e02a5a62f880969a811eacc2d16816bf105f115c51f09ce118c4872354f9933
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Engberg, AdamStelzl, ChristinaEriksson, OlleO'Callaghan, PaulKreuger, Johan

Search in DiVA

By author/editor
Engberg, AdamStelzl, ChristinaEriksson, OlleO'Callaghan, PaulKreuger, Johan
By organisation
Department of Medical Cell Biology
In the same journal
Scientific Reports
Biomaterials Science

Search outside of DiVA

GoogleGoogle Scholar
Total: 442 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 327 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf